This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Shah, V. O. Articles by Zager, P. G. Search for Related Content PubMed PubMed Citation Articles by Shah, V. O. Articles by Zager, P. G.

Aldose Reductase Gene Expression Is Increased in Diabetic Nephropathy¹

Department of Internal Medicine, University of New Mexico Health Sciences Center (V.O.S., Y.S., M.B., P.G.Z.) Albuquerque 87131; the Veterans Administration Medical Center (R.I.D.), Albuquerque, New Mexico 87108

Address all correspondence and requests for reprints to: Dr. Philip Zager, Department of Internal Medicine, University of New Mexico Health Sciences Center, Fifth Floor ACC, 2211 Lomas NE, Albuquerque, New Mexico 87131.

Aldose reductase gene expression is increased in insulin-dependent diabetes mellitus (IDDM) with nephropathy. Epidemiology studies in patients with IDDM and noninsulin-dependent diabetes mellitus (NIDDM) are consistent with the hypothesis that a genetic factor(s) influences the risk for kidney disease of diabetes mellitus (KDDM). Aldose reductase (AR), the rate-limiting enzyme in the polyol pathway, is a potential candidate gene product. The present study explored the hypothesis that AR gene expression is increased in peripheral blood mononuclear cells obtained from patients with KDDM. We studied four groups of volunteers: group I, normal subjects; group II, IDDM without nephropathy; group III, IDDM with kidney disease; and group IV, nondiabetics with kidney disease. AR messenger ribonucleic acid was measured by a ribonuclease protection assay. The results are expressed as the mean and 95% confidence interval (CI) of the AR/ß-actin messenger ribonucleic acid molar ratios (AR/ß-actin R). Among diabetics, the AR/ß-actin R was higher in group III (0.088; CI, 0.068–0.108) than in group I (0.045; CI, 0.033–0.057; P < 0.01). There were no significant differences in age, hemoglobin A_1c, or duration of diabetes between groups II and III (P = NS). The AR/ß-actin R in group III was also higher than that in group II (0.045; CI, 0.030–0.060; P < 0.01) or group IV (0.019; CI, 0.011–0.027; P < 0.001). In contrast, among nondiabetics, AR/ß-actin R values were 2-fold lower in group IV than in group I (P < 0.01). The results of this study are consistent with the hypothesis that the degree of AR gene expression modulates the risk of KDDM.

This article has been cited by other articles:

				M. Xu, X. Chen, L. Yan, H. Cheng, and W. Chen Association between (AC)n dinucleotide repeat polymorphism at the 5'-end of the aldose reductase gene and diabetic nephropathy: a meta-analysis J. Mol. Endocrinol., May 1, 2008; 40(5): 243 - 251. [Abstract] [Full Text] [PDF]

				B. Yang, A. D. Hodgkinson, P. J. Oates, H. M. Kwon, B. A. Millward, and A. G. Demaine Elevated activity of transcription factor nuclear factor of activated T-cells 5 (NFAT5) and diabetic nephropathy. Diabetes, May 1, 2006; 55(5): 1450 - 1455. [Abstract] [Full Text] [PDF]

				S. R. Danielson, V. Carelli, G. Tan, A. Martinuzzi, A. H. V. Schapira, M.-L. Savontaus, and G. A. Cortopassi Isolation of transcriptomal changes attributable to LHON mutations and the cybridization process Brain, May 1, 2005; 128(5): 1026 - 1037. [Abstract] [Full Text] [PDF]

				B. F. Schrijvers, A. S. De Vriese, and A. Flyvbjerg From Hyperglycemia to Diabetic Kidney Disease: The Role of Metabolic, Hemodynamic, Intracellular Factors and Growth Factors/Cytokines Endocr. Rev., December 1, 2004; 25(6): 971 - 1010. [Abstract] [Full Text] [PDF]

				T. Wendt, N. Tanji, J. Guo, B. I. Hudson, A. Bierhaus, R. Ramasamy, B. Arnold, P. P. Nawroth, S. F. Yan, V. D'Agati, et al. Glucose, Glycation, and RAGE: Implications for Amplification of Cellular Dysfunction in Diabetic Nephropathy J. Am. Soc. Nephrol., May 1, 2003; 14(5): 1383 - 1395. [Abstract] [Full Text] [PDF]

				C. I. Whiteside and J. A. Dlugosz Mesangial cell protein kinase C isozyme activation in the diabetic milieu Am J Physiol Renal Physiol, June 1, 2002; 282(6): F975 - F980. [Abstract] [Full Text] [PDF]